All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Zai Lab reports sustained biomarker inhibition with ZL-1503 in Phase 1 trial

By Public Technologies
  • Zai Lab announced positive preliminary results for experimental atopic dermatitis treatment ZL-1503 in healthy volunteers in a Phase 1/1b trial.
  • The drug showed sustained suppression of inflammatory biomarkers, with no serious adverse events or dose-limiting toxicities reported.
  • Its extended half-life supports further evaluation of maintenance dosing once every 12 weeks.
  • Results will be presented at the American College of Allergy, Asthma & Immunology meeting on November 13, 2026.
  • Repeated-dose results in patients with moderate-to-severe atopic dermatitis are expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261113823642) on November 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.